A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene; a preliminary results of WJTOG 3405

被引：5

作者：

Tsurutani, J. ^{[1
]}

Mitsudomi, T. ^{[3
]}

Mori, S. ^{[2
]}

Okamoto, I. ^{[1
]}

Kaname, N. ^{[4
]}

Tada, H. ^{[5
]}

Negoro, S. ^{[6
]}

Yatabe, Y. ^{[7
]}

Fukuoka, M. ^{[8
]}

Nakagawa, K. ^{[1
]}

机构：

[1] Kinki Univ, Sch Med, Osakasayama, 232, Japan

[2] Yokohama City Univ, Yokohama, Kanagawa, Japan

[3] Aichi Canc Ctr, Nagoya, Aichi, Japan

[4] Kyushu Natl Canc Ctr, Fukuoka, Japan

[5] Osaka City Gen Hosp, Osaka, Japan

[6] Hyogo Canc Ctr, Akashi, Hyogo 464, Japan

[7] Aichi Canc Ctr, Nagoya, Aichi, Japan

[8] Kinki Univ, Sakai Hosp, Sch Med, Sakai, Osaka, Japan

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71715-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：505 / 505

页数：1